PTC Therapeutics, Inc. insider trading
Every open-market purchase and sale by PTC Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following PTC Therapeutics, Inc.’s insiders pay?
From December 19, 2013 to September 11, 2025, 18 insiders reported 6 open-market purchases and 85 sales not made under a pre-set plan in PTC Therapeutics, Inc. Twelve months after each purchase was reported, the shares were +40.3% against the S&P 500 on average (median +40.6%), over 6 purchases with a full year of prices; 83% beat the index. After sales, the shares moved −17.0% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on September 9, 2014 into $149,712 by November 2, 2026, +25.0% a year. It held shares 46% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $40,775 (+12.3% a year), and held throughout $46,532 (+13.5%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Peltz Stuart Walter | CHIEF EXECUTIVE OFFICER | 0 | — | — | 16 | −11.7% (16) | February 2, 2023 |
| Pauwels Eric | CHIEF EXECUTIVE OFFICER | 0 | — | — | 14 | −16.7% (14) | April 19, 2024 |
| Hill Emily Luisa | CHIEF FINANCIAL OFFICER | 0 | — | — | 11 | −34.2% (11) | February 2, 2023 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | 0 | — | — | 10 | −17.4% (10) | February 2, 2023 |
| Boulding Mark Elliott | EXEC. VP AND CLO | 0 | — | — | 7 | −38.1% (7) | February 2, 2023 |
| Svoronos Dawn | Director | 1 | +126.8% (1) | 100% | 5 | −11.9% (5) | June 10, 2022 |
| Utter Christine Marie | SVP, FINANCE & CAO | 0 | — | — | 6 | −36.9% (6) | February 2, 2023 |
| Klein Matthew B. | CHIEF OPERATING OFFICER | 0 | — | — | 4 | −15.3% (4) | January 12, 2023 |
| Okey Stephanie | Director | 0 | — | — | 4 | −14.8% (4) | March 17, 2025 |
| Schmertzler Michael | Director | 3 | +11.2% (3) | 67% | 0 | — | March 18, 2020 |
| Jacobson Allan Steven | Director | 0 | — | — | 2 | +9.3% (2) | September 2, 2025 |
| Souza Marcio | Chief Operating Officer | 0 | — | — | 2 | +3.4% (2) | June 4, 2019 |
| Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER | 0 | — | — | 1 | +50.2% (1) | April 4, 2024 |
| Gravier Pierre | CHIEF FINANCIAL OFFICER | 1 | +35.6% (1) | 100% | 0 | — | December 14, 2023 |
| Hbm Healthcare Investments (cayman) Ltd. | 10% owner | 0 | — | — | 1 | +176.8% (1) | December 19, 2013 |
| Rothera Mark | Chief Commercial Officer | 1 | +45.6% (1) | 100% | 0 | — | March 7, 2016 |
| Southwell David P | Director | 0 | — | — | 1 | −9.0% (1) | September 11, 2025 |
| Young Alethia | Director | 0 | — | — | 1 | −45.1% (1) | September 8, 2023 |
When several insiders traded PTC Therapeutics, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of PTC Therapeutics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 7 selling crowds, −6.4%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| January 31, 2023 | 7 selling | +18.3% | −24.0% | −65.5% |
| August 31, 2022 | 3 selling | −20.5% | −10.9% | −35.8% |
| June 30, 2022 | 4 selling | +29.1% | −10.0% | −16.2% |
| January 31, 2022 | 8 selling | −2.5% | +25.2% | +25.0% |
| January 29, 2021 | 7 selling | −41.9% | −53.0% | −53.5% |
| January 31, 2020 | 3 selling | +4.8% | −12.6% | −8.9% |
| January 31, 2019 | 3 selling | +11.7% | +40.4% | +44.0% |